Scope
CDC’s 2022 guidance concerns outpatients aged 18 years or older with acute, subacute or chronic pain. It excludes sickle-cell pain, cancer-related pain, palliative care and end-of-life care. Its central approach is individualised multimodal pain treatment, shared goals and ongoing reassessment. Starting opioids and reducing established treatment require different benefit–risk decisions; numerical guideposts must not become compulsory dose ceilings or forced rapid tapers.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Decide whether an opioid adds benefit
- For many common acute pain conditions, nonopioid treatments are at least as effective. Maximise appropriate nonpharmacological and nonopioid options, and consider an opioid only when expected benefit outweighs risk after discussing realistic outcomes and harms (CDC category B, evidence type 3). [1]
- Prefer nonopioid therapies for subacute or chronic pain. Consider starting an opioid only when expected pain and functional benefits outweigh risks; agree goals and an exit strategy if benefits are inadequate (category A, evidence type 2). This does not require failure of every alternative first. [1]
- When starting opioids for acute, subacute or chronic pain, select immediate-release rather than extended-release/long-acting formulations (category A, evidence type 4). Do not use extended-release/long-acting opioids for acute pain or intermittent/as-needed treatment. [1]
- For an opioid-naïve patient, start at the lowest effective dose, adjusted to clinical circumstances and renal or hepatic function. If continuing treatment, reassess individual benefit and risk before any increase and avoid escalation with diminishing benefit (category A, evidence type 3). [1]
- Before increasing total opioid exposure to ≥50 MME/day, pause and reassess. At or above 50 MME/day from combined opioid sources, excluding buprenorphine from MME calculations, increase follow-up and offer naloxone and overdose education. These are guideposts, not rigid ceilings; lower doses also carry risk. [1]
- Use morphine-milligram equivalents only as approximate exposure measures, not as a prescription for switching opioids. Incomplete cross-tolerance and variable pharmacokinetics require separate conversion judgement; pain-related conversion factors do not govern opioid-use-disorder dosing. [1]
Prescribe deliberately and review early
- For acute pain warranting an opioid, prescribe only the quantity needed for the expected period of severe pain (category A, evidence type 4) and advise use as needed. A few days often suffice for nontraumatic, nonsurgical pain, but duration is individualised; continuous use beyond a few days warrants a brief taper. [1]
- Review patients at least every 2 weeks while opioids continue for acute pain. At 30 days, reassess pain, function, reversible causes and the treatment course; continued prescribing should represent an intentional long-term benefit–risk decision, not an automatic refill. [1]
- After starting opioids for subacute/chronic pain or increasing dose, assess benefit and risk within 1–4 weeks (category A, evidence type 4). Reassess long-term treatment about every 3 months or more often, using shorter intervals for higher-risk patients and reviewing pain, function, adverse effects and patient goals. [1]
- Methadone is not the first choice of a long-acting opioid for pain. Prescribers need familiarity with its risks, QT assessment and close monitoring; strongly consider review every 2–3 days during the first week after initiation or dose increase because accumulation is unpredictable. [1]
Reduce established treatment without abandoning care
- For patients already receiving opioids, continue while optimising nonopioid care when benefits outweigh risks. If risks predominate, work together toward gradual dose reduction or discontinuation. Do not abruptly stop or rapidly reduce higher doses unless a life-threatening problem, such as impending overdose, requires it (category B, evidence type 4). [1]
- Agree an individual taper and review at least monthly. After long-term use such as ≥1 year, reductions of 10% per month or slower are often better tolerated. Slow or pause when withdrawal is significant; the objective may be a safer dose rather than complete cessation. [1]
- During tapering, support pain and mental-health care, screen for depression, anxiety and opioid misuse, and warn that returning abruptly to the former dose can cause overdose after tolerance falls. Provide overdose education and offer naloxone; disagreement about tapering must not lead to abandonment. [1]
Anticipate overdose and medication harms
- Before starting and periodically during opioids, evaluate and discuss harms and incorporate naloxone into risk mitigation (category A, evidence type 4). Prioritise offers with overdose/substance-use history, sleep-disordered breathing, ≥50 MME/day, concurrent benzodiazepines or lost tolerance; teach patients its use and offer household education. [1]
- Avoid opioids where possible in moderate or severe sleep-disordered breathing. Use extra caution and monitoring with renal/hepatic impairment or age ≥65; assess falls, cognition and constipation, and whether sedation compromises driving or other hazardous work. [1]
- In pregnancy, weigh analgesic benefits and risks together; seek expertise before tapering established opioids because withdrawal may harm the pregnant patient and fetus. For opioid use disorder, offer buprenorphine or methadone as early as possible rather than withdrawal-only management. [1]
- Review controlled-drug prescription history through the available US PDMP when initiating opioids and during chronic treatment (category B, evidence type 4). Ideally check before every prescription when practicable; for long-term therapy, check initially and at least every 3 months, considering other prescribers and sedating combinations. [1]
- Discuss unexpected prescription-monitoring information with the patient, verify it and coordinate with other prescribers. Do not dismiss a patient because of PDMP findings, and do not substitute an unvalidated automated risk score for clinical judgement. [1]
- For subacute/chronic opioid therapy, consider the benefits and risks of toxicology testing before treatment and periodically, at least annually (category B, evidence type 4). Explain its safety purpose, avoid selective biased use, and never use a result punitively or as grounds for dismissal. [1]
- Interpret toxicology in context: routine opiate screens may miss fentanyl and other opioids, and a positive result may reflect metabolism of a prescribed drug. Discuss unexplained findings nonjudgmentally and use selective confirmatory testing when results materially affect care or an unexpected screen remains unexplained. [1]
Coordinate sedating drugs and treat opioid use disorder
- Use particular caution with opioids plus benzodiazepines, and weigh benefits against risks with other central nervous system depressants (category B, evidence type 3). Coordinate care; if benzodiazepine reduction is indicated, taper gradually and individually because abrupt withdrawal may cause seizures or other serious harm. [1]
- Assess suspected opioid use disorder clinically using DSM criteria and offer or arrange evidence-based medication treatment (category A, evidence type 1). Detoxification alone is not recommended because return to use and fatal overdose risks increase. Continue pain care and do not dismiss the patient because of the disorder. [1]
- Do not withhold buprenorphine or methadone for opioid use disorder solely because benzodiazepines or other depressants are used; manage the interaction. Pain-dose thresholds do not apply to opioid agonist treatment of the disorder, and unavailable or declined psychosocial treatment should not delay medication. [1]
- Explain respiratory-depression and dependence risks, safe driving, constipation prevention, secure, preferably locked storage and disposal of unused opioids. With opioid/acetaminophen combinations, warn against unrecognised additional acetaminophen. [1]
Limitations and use
- This summary reflects the 2022 US clinical guideline. It does not establish current prescribing law, controlled-drug registration, buprenorphine-waiver requirements, local monitoring-system access or Indian regulatory requirements.
- The outpatient pain recommendations exclude sickle-cell pain, cancer-related pain, palliative care and end-of-life care; they are not a paediatric prescribing protocol or a complete inpatient analgesia protocol.
- Dose guideposts are not mandatory ceilings. This summary does not provide opioid-conversion prescriptions, complete withdrawal treatment, naloxone dosing or medication-induction regimens for opioid use disorder. Use appropriate clinical expertise and current product information.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- CDC clinical practice guideline for prescribing opioids for pain
Selected recommendation material consulted
Publication details
- Issuing organisation
- CDC
- First published
- 4 November 2022
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.